Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut

The goal of this observational study is to detect the prevalence of NAFLD in CKD patients

The main question[s] it aims to answer are:

• [question 1] prevalence of NAFLD in CKD patients.
• [question 2] the relationship between NAFLD and CKD.

Study Overview

• Status: Not yet recruiting
• Conditions: NAFLD; CKD

Detailed Description

The goal of this observational study is to detect the prevalence of NAFLD in CKD patients

The main question[s] it aims to answer are:

• [question 1] prevalence of NAFLD in CKD patients.
• [question 2] the relationship between NAFLD and CKD.

• Study Type: Observational
• Enrollment (Estimated): 200

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

CKD patients

Description

Inclusion Criteria:

• CKD patients

Exclusion Criteria:

• HCV and HBV Positive patients
• Alcoholics
• patient on Hemodialysis
• patients with wilson disease
• patients with alpha one antitrypsin deficiency

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
CKD patients; CKD patient who are not DM are investigated for the presence of NAFLD
normal control group; normal population are investigated to know the prevalence of NAFLD in contrast to patients with CKD.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
abdominal ultrasound	assessment of Liver regarding fatty liver disease by Ultrasound.	1 year
liver enzymes	participants will undergo assessment of liver enzymes (AST and ALT) and results will be reporeted in a table.	1 year
Fibroscan	participants will undergo fibroscanning of the liver to assess NAFLD and results will be reported in a table.	1 year
BUN, Cr level and estimated GFR	participants will be assessed regarding BUN, CR and estimated GFR to confirm and follow up CKD patients involved in the study.	1 year
Lipid Profile	participants will be assessed regarding Cholesterol level, Triglycerides, HDL and LDL. results will be reported in a table	1 year
Complete Blood Picture (WBCs, HB, Patelets	total leucocytic count Hemoglobin level and platelet count will be assessed in our patients and will be reported in a table	1 year
serum Uric Acid	serum uric acid will be assessed and reported in our patients	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Waist Circumference	waist circumference measurement.	1 year
Body Mass Index	BMI will also be calculated.	1 year

Collaborators and Investigators

• Sponsor: Muhammad Ameen Abdelrady Abdelaziz

Study record dates

Study Major Dates

• Study Start (Estimated): December 1, 2023
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): December 1, 2024

Study Registration Dates

• First Submitted: July 28, 2023
• First Submitted That Met QC Criteria: August 22, 2023
• First Posted (Actual): August 24, 2023

Study Record Updates

• Last Update Posted (Actual): August 24, 2023
• Last Update Submitted That Met QC Criteria: August 22, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Urologic Diseases; Disease Attributes; Renal Insufficiency; Chronic Disease; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Liver Diseases; Kidney Diseases; Renal Insufficiency, Chronic; Fatty Liver; Non-alcoholic Fatty Liver Disease
• Other Study ID Numbers: NAFLD and CKD